Nestle works on new range of weight-loss drug companion products as sales miss estimates

Nestle posted worse-than-expected results for the first nine months of 2023 as its revenues were hit by divestments and unfavorable exchange rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.